Literature DB >> 10949306

Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice.

S E Artandi1, S Chang, S L Lee, S Alson, G J Gottlieb, L Chin, R A DePinho.   

Abstract

Aged humans sustain a high rate of epithelial cancers such as carcinomas of the breast and colon, whereas mice carrying common tumour suppressor gene mutations typically develop soft tissue sarcomas and lymphomas. Among the many factors that may contribute to this species variance are differences in telomere length and regulation. Telomeres comprise the nucleoprotein complexes that cap the ends of eukaryotic chromosomes and are maintained by the reverse transcriptase, telomerase. In human cells, insufficient levels of telomerase lead to telomere attrition with cell division in culture and possibly with ageing and tumorigenesis in vivo. In contrast, critical reduction in telomere length is not observed in the mouse owing to promiscuous telomerase expression and long telomeres. Here we provide evidence that telomere attrition in ageing telomerase-deficient p53 mutant mice promotes the development of epithelial cancers by a process of fusion-bridge breakage that leads to the formation of complex non-reciprocal translocations--a classical cytogenetic feature of human carcinomas. Our data suggest a model in which telomere dysfunction brought about by continual epithelial renewal during life generates the massive ploidy changes associated with the development of epithelial cancers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10949306     DOI: 10.1038/35020592

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  360 in total

1.  How do tumors make ends meet?

Authors:  C Lengauer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

Review 2.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

3.  Rapid upregulation of telomerase activity in human leukemia HL-60 cells treated with clinical doses of the DNA-damaging drug etoposide.

Authors:  T J Moriarty; S Dupuis; C Autexier
Journal:  Leukemia       Date:  2002-06       Impact factor: 11.528

4.  DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.

Authors:  W M Tong; M P Hande; P M Lansdorp; Z Q Wang
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

5.  Spontaneous transformation of murine epithelial cells requires the early acquisition of specific chromosomal aneuploidies and genomic imbalances.

Authors:  Hesed M Padilla-Nash; Karen Hathcock; Nicole E McNeil; David Mack; Daniel Hoeppner; Rea Ravin; Turid Knutsen; Raluca Yonescu; Danny Wangsa; Kathleen Dorritie; Linda Barenboim; Yue Hu; Thomas Ried
Journal:  Genes Chromosomes Cancer       Date:  2011-12-08       Impact factor: 5.006

Review 6.  How long should telomeres be?

Authors:  A Aviv; C B Harley
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

7.  Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma.

Authors:  Lawrence N Kwong; Lihua Zou; Sharmeen Chagani; Chandra Sekhar Pedamallu; Mingguang Liu; Shan Jiang; Alexei Protopopov; Jianhua Zhang; Gad Getz; Lynda Chin
Journal:  Cell Rep       Date:  2017-05-16       Impact factor: 9.423

8.  A mouse model of human oral-esophageal cancer.

Authors:  Oliver G Opitz; Hideki Harada; Yasir Suliman; Ben Rhoades; Norman E Sharpless; Ralph Kent; Levy Kopelovich; Hiroshi Nakagawa; Anil K Rustgi
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

9.  Different telomere damage signaling pathways in human and mouse cells.

Authors:  Agata Smogorzewska; Titia de Lange
Journal:  EMBO J       Date:  2002-08-15       Impact factor: 11.598

10.  Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT.

Authors:  Alexander Röth; Gabriela M Baerlocher; Mike Schertzer; Elizabeth Chavez; Ulrich Dührsen; Peter M Lansdorp
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.